Segment Information

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Segment Information

Segment Information

We operate as one operating segment, which is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders, and, therefore, our chief operating decision-maker manages the operations of our company as a single operating segment. Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.

Revenue by product is summarized as follows:

	For the Years Ended December 31,
	2014						2013						2012
(In millions)	United States		Rest of World		Total		United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis (MS):
AVONEX	$	1,956.7	$	1,056.4	$	3,013.1	$	1,902.4	$	1,103.1	$	3,005.5	$	1,793.7	$	1,119.4	$	2,913.1
PLEGRIDY	27.8		16.7		44.5		—		—		—		—		—		—
TECFIDERA	2,426.6		482.6		2,909.2		864.4		11.7		876.1		—		—		—
TYSABRI	1,025.1		934.4		1,959.5		814.2		712.3		1,526.5		383.1		752.8		1,135.9
FAMPYRA	—		80.2		80.2		—		74.0		74.0		—		57.4		57.4
Hemophilia:
ALPROLIX	72.1		3.9		76.0		—		—		—		—		—		—
ELOCTATE	58.4		—		58.4		—		—		—		—		—		—
Other product revenues:
FUMADERM	—		62.5		62.5		—		60.2		60.2		—		59.7		59.7
Total product revenues	$	5,566.7	$	2,636.7	$	8,203.4	$	3,581.0	$	1,961.3	$	5,542.3	$	2,176.8	$	1,989.3	$	4,166.1

Geographic Information

The following tables contain certain financial information by geographic area:

December 31, 2014 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	5,566.7	$	1,383.9	$	811.8	$	112.8	$	328.2	$	8,203.4
Revenues from unconsolidated joint business	$	1,117.1	$	7.7	$	—	$	—	$	70.6	$	1,195.4
Other revenues from external customers	$	212.6	$	31.6	$	1.8	$	58.5	$	—	$	304.5
Long-lived assets	$	1,055.5	$	701.9	$	2.5	$	2.6	$	3.2	$	1,765.7
December 31, 2013 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	3,581.0	$	1,170.2	$	417.7	$	93.2	$	280.2	$	5,542.3
Revenues from unconsolidated joint business	$	1,087.3	$	1.6	$	—	$	3.2	$	33.9	$	1,126.0
Other revenues from external customers	$	193.5	$	26.1	$	1.2	$	43.1	$	—	$	263.9
Long-lived assets	$	984.4	$	758.3	$	2.5	$	2.1	$	3.3	$	1,750.7
December 31, 2012 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	2,176.8	$	1,216.2	$	409.2	$	93.2	$	270.7	$	4,166.1
Revenues from unconsolidated joint business	$	1,033.3	$	14.3	$	—	$	27.5	$	62.8	$	1,137.9
Other revenues from external customers	$	170.2	$	27.9	$	1.1	$	13.3	$	—	$	212.5
Long-lived assets	$	996.6	$	738.6	$	1.9	$	2.9	$	2.2	$	1,742.2

(1) Represents amounts related to Europe less those attributable to Germany.

Revenues from Unconsolidated Joint Business

Approximately 12%, 16% and 21% of our total revenues in 2014, 2013 and 2012, respectively, are derived from our joint business arrangement with Genentech. For additional information related to our collaboration with Genentech, please read Note 20, Collaborative and Other Relationships to these consolidated financial statements.

Significant Customers

We recorded revenue from two wholesalers accounting for 33% and 27% of gross product revenues in 2014, 32% and 24% of gross product revenues in 2013, and 20% and 10% of gross product revenues in 2012, respectively.

Other

As of December 31, 2014, 2013 and 2012, approximately $676.0 million, $731.1 million and $713.4 million, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark. For 2014 compared to 2013, the decrease in the balance of our manufacturing facilities in Denmark was due to foreign currency exchange rates.